1. Imanshahidi M et al. Berberine and barberry (Berberis vulgaris): A clinical review. Phytother Res. 2019;33(3):504-523.
2. Feng X et al. Berberine in cardiovascular and metabolic diseases: from mechanisms to therapeutics. Theranostics. 2019;9(7):1923-1951.
3. Birdsall TC et al. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Rev. 1997;2(2): 94-103.
4. Chu M et al. Berberine: a medicinal compound for the treatment of bacterial infections. Clin Microbial. 2014;3:150.
5. Neag MA et al. Berberine: botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. Front Pharmacol. 2018;9:557.
6. Bone K et al. Berberis bark and Hydrastis root. In: Principles and practice of phytotherapy. Elsevier 2013;399-418. ISBN 978-0-445-06992-5.
7. Zhang H et al. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism. 2010;59(2):285-92.
8. Ahmed T et al. Berberine and neurodegeneration: A review of literature. Pharmacol Rep. 2015;67(5):970-9.
9. Yuan ZY et al. TATA boxes in gene transcription and poly (A) tails in mRNA stability: New perspective on the effects of berberine. Sci Rep. 2015;5:18326.
10. Habtemariam S. Berberine and inflammatory bowel disease: a concise review. Pharmacol Res. 2016;113(A):592-599.
11. Zhu X et al. The preconditioning of berberine suppresses hydrogen peroxide-induced premature senescence via regulation of sirtuin 1. Oxid Med Cell Longev. 2017;2017:2391820.
12. Lan J et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69-81.
13. Bertuccioli A et al. Berberine and dyslipidemia: different applications and biopharmaceutical formulations without statin-like molecules-a meta-analysis. J Med Food. 2019 Aug 23.
14. Wang Y et al. Update on the benefits and mechanisms of action of the bioactive vegetal alkaloid berberine on lipid metabolism and homeostasis. Cholesterol. 2018;2018:7173920.
15. Di Pierro F et al. Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. Clin Pharmacol. 2013;5:167-74.
16. Zhang H et al. Enhancement of berberine hypoglycemic activity by oligomeric proanthocyanidins. Molecules. 2018;23(12):3318.
17. Tan XS et al. Tissue distribution of berberine and its metabolites after oral administration in rats. PLoS One 2013;8:e77969.
18. Kumar A et al. Current knowledge and pharmacological profile of berberine: an update. Eur J Pharmacol. 2015;761:288-97.
19. Spinozzi S et al. Berberine and its metabolites: relationship between physicochemical properties and plasma levels after administration to human subjects. J Nat Prod. 2014;77(4):766-72.
20. Yuan ZY et al. TATA boxes in gene transcription and poly (A) tails in mRNA stability: New perspective on the effects of berberine. Sci Rep. 2015;5:18326.
21. Zou K et al. Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and antitumor effects in the digestive system. Acta Pharmacol Sin. 2017;38(2):157-167.
22. Wang Z et al. Berberine ameliorates collagen-induced arthritis in rats associated with anti-inflammatory and anti-angiogenic effects. Inflammation 2014;37(5):1789-1798.
23. Dong H et al. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654.
24. Li Z et al. Berberine improves airway inflammation and inhibits NF-κB signaling pathway in an ovalbumininduced rat model of asthma. J Asthma. 2016;53(10):999-1005.
25. Chelakkot C et al. Mechanisms regulating intestinal barrier integrity and its pathological implications. Exp Mol Med. 2018;50(8):103.
26. Fan J et al. Pharmacological effects of berberine on mood disorders. J Cell Mol Med. 2019;23(1):21-28.
27. Fan D et al. Combating neurodegenerative diseases with the plant alkaloid berberine: molecular mechanisms and therapeutic potential. Curr Neuropharmacol. 2019;17(6):563-579.
28. Yan HM et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PloS one 2015;10:e0134172.
29. Pirillo A et al. Berberine, a plant alkaloid with lipid- and glucose-lowering properties: from in vitro evidence
to clinical studies. Atherosclerosis. 2015;243(2):449-61.
30. Abd El-Wahab AE et al. In vitro biological assessment of Berberis vulgaris and its active constituent, berberine: antioxidants, anti-acetylcholinesterase, anti-diabetic and anticancer effects. BMC Complement Altern Med. 2013;13:218.
31. Song S et al. Downregulation of cellular c-Jun N-terminal protein kinase and NF-κB activation by berberine may result in inhibition of herpes simplex virus replication. Antimicrob Agents Chemother. 2014;58(9):5068-78.
32. Freile ML et al. Antimicrobial activity of aqueous extracts and of berberine isolated from Berberis heterophylla. Fitoterapia. 2003;74(7-8):702-5.
33. Lv Z et al. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment. Antimicrob Agents Chemother. 2015;59(7):3726-35.
34. Jeong HW et al. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am J Physiol Endocrinol Metab. 2009;296(4):E955-64.
35. Chu M et al. Role of berberine in anti-bacterial as a high-affinity LPS antagonist binding to TLR4/MD-2 receptor. BMC Complement Altern Med. 2014;14:89.
36. Imanshahidi M et al. Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine. Phytother Res. 2008;22(8):999-1012.
37. Sun D et al. Influence of berberine sulfate on synthesis and expression of Pap fimbrial adhesin in uropathogenic Escherichia coli. Antimicrob Agents Chemother. 1988;32:1274-1277.
38. Zhang S et al.(2018). The effect of berberine on the transcriptome and proteome of E. coli. bioRxiv. https://doi.org/10.1101/318733.
39. Shi C et al. Combination of berberine and ciprofloxacin reduces multi-resistant Salmonella strain biofilm formation by depressing mRNA expressions of luxS, rpoE, and ompR. J Vet Sci. 2018;19(6):808-816.
40. Thoulouze MI et al. Can viruses form biofilms? Trends Microbiol. 2011;19(6):257-62.
41. Costa-Orlandi CB et al. Fungal biofilms and polymicrobial diseases. J Fungi (Basel). 2017;3(2):22.
42. Xiang DY et al. The effects of berberine on Clostridium perfringens induced necrotic enteritis in broiler chickens. Arch Clin Microbiol. 2017;8:3.
43. Boberek JM et al. Genetic evidence for inhibition of bacterial division protein FtsZ by berberine. PLoS ONE 2010;5:e13745.
44. Wojtyczka RD et al. Berberine enhances the antibacterial activity of selected antibiotics against coagulasenegative staphylococcus strains in vitro. Molecules 2014;19:6583-6596.
45. Mahmoudvand H et al. In vivo evaluation of Berberis vulgaris extract on acute toxoplasmosis in mice. Marmara Pharmaceut J. 2017;21(3):558-563.
46. Bhandari DK et al. Antimicrobial activity of crude extracts from Berberis asiatica stem bark. Pharmaceut Biol. 2000;38(4):254-257.
47. Yu HH et al. Antimicrobial activity of berberine alone and in combination with ampicillin or oxacillin against methicillin-resistant Staphylococcus aureus. J Med Food. 2005;8(4):454-61.
48. Sun D et al. Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin, and hexadecane. Antimicrob Agents Chemother. 1998;32:1370-1374.
49. Kuang TJ et al. In vitro antibacterial effects of berberine on mycobacterium tuberculosis. Zhong Guo Zhong Yao Za Zhi 2001;26:867-8.
50. Wang D et al. Global transcriptional profiles of Staphylococcus aureus treated with berberine chloride. FEMS Microbiol Lett. 2008;279(2):217-25.
51. Tan J et al. Antimicrobial characteristics of berberine against prosthetic joint infection-related Staphylococcus aureus of different multilocus sequence types. BMC Complement Altern Med. 2019;19(1):218.
52. Shen YB et al. The effects of berberine on the magnitude of the acute inflammatory response induced by Escherichia coli lipopolysaccharide in broiler chickens. Poult Sci. 2010;89(1):13-9.
53. Khin-Maung-U et al. Clinical trial of berberine in acute watery diarrhoea. Br Med J (Clin Res Ed). 1985;291(6509):1601-5.
54. Zhang D et al. Berberine containing quadruple therapy for initial Helicobacter pylori eradication: an openlabel randomized phase IV trial. Medicine (Baltimore). 2017;96(32):e7697.
55. Wu X et al. Berberine demonstrates anti-inflammatory properties in Helicobacter pylori-infected mice with chronic gastritis by attenuating the Th17 response triggered by the B cell-activating factor. J Cell Biochem. 2018;119(7):5373-5381.
56. Jiang X et al. Berberine combined with triple therapy versus triple therapy for Helicobacter pylori eradication: a meta-analysis of randomized controlled trials. Evid Based Complement Alternat Med. 2018;2018:8716910.
57. Zhi D et al. The enhancement of cardiac toxicity by concomitant administration of berberine and macrolides. Eur J Pharm Sci. 2015;76:149-55.
58. Hu JP et al. Coptidis rhizoma inhibits growth and proteases of oral bacteria. Oral Dis. 2000;6:297-302.
59. Hung TC et al. Berberine inhibits hepatitis C virus entry by targeting the viral E2 glycoprotein. Phytomedicine. 2019;53:62-69.
60. Yan YQ et al. Anti-influenza activity of berberine improves prognosis by reducing viral replication in mice. Phytother Res. 2018;32(12):2560-2567.
61. Wu Y et al. In vivo and in vitro antiviral effects of berberine on influenza virus. Chin J Integr Med. 2011;17(6):444-52.
62. Chin LW et al. Anti-herpes simplex virus effects of berberine from Coptidis rhizoma, a major component of a Chinese herbal medicine, Ching-Wei-San. Arch Virol. 2010;155:1933-1941.
63. Wang H et al. Berberine inhibits enterovirus 71 replication by downregulating the MEK/ERK signaling pathway and autophagy. Virol J. 2017;14(1):2.
64. Hayashi K et al. Antiviral activity of berberine and related compounds against human cytomegalovirus. Bioorg Med Chem Lett. 2007;17:1562-1564.
65. Luganini A et al. The isoquinoline alkaloid berberine inhibits human cytomegalovirus replication by interfering with the viral Immediate Early-2 (IE2) protein transactivating activity. Antiviral Res. 2019;164:52-60.
66. Dai Q et al. Berberine restricts coxsackievirus B type 3 replication via inhibition of c-Jun N-Terminal Kinase (JNK) and p38 MAPK activation in vitro. Med Sci Monit. 2017;23:1448-1455.
67. Shin HB et al. Inhibition of respiratory syncytial virus replication and virus-induced p38 kinase activity by berberine. Int Immunopharmacol. 2015;27(1):65-68.
68. Batista MN et al. Natural products isolated from oriental medicinal herbs inactivate zika virus. Viruses. 2019;11(1).
69. Varghese FS et al. Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses. Antivir Res. 2016;126:117-124.
70. Varghese FS et al. The antiviral alkaloid berberine reduces Chikungunya virus-induced mitogen-activated protein kinase signaling. J Virol. 2016;90(21):9743-9757.
71. Yang Z et al. Fluconazole inhibits cellular ergosterol synthesis to confer synergism with berberine against yeast cells. J Glob Antimicrob Resist. 2018;13:125-130.
72. Iwazaki RS et al. In vitro antifungal activity of the berberine and its synergism with fluconazole. Antonie Van Leeuwenhoek. 2010;97(2):201-5.
73. Dhamgaye S et al. Molecular mechanisms of action of herbal antifungal alkaloid berberine, in Candida albicans. PLoS ONE 2014;9(8):e104554.
74. Han Y et al. Berberine synergy with amphotericin B against disseminated candidiasis in mice. Biol Pharm Bull. 2005;28(3):541-4.
75. Luo H et al. In vitro susceptibility of berberine combined with antifungal agents against the yeast form of Talaromyces marneffei. Mycopathologia. 2019;184(2):295-301.
76. Kaneda Y et al. In vitro effects of berberine sulfate on the growth of Entamoeba histolytica, Giardia lamblia and Tricomonas vaginalis. AnnTrop Med Parasitol. 1991;85:417-425.
77. Gupte S. Use of berberine in treatment of giardiasis. Am J Dis Child. 1975;129:866.
78. De Sarkar S et al. Berberine chloride mediates its antileishmanial activity by inhibiting Leishmania mitochondria. Parasitol Res. 2019;118(1):335-345.
79. Vennerstrom JL et al. Berberine derivatives as anti-leishmanial drugs. Antimicrob Agent Chemother. 2005;34:198-211.
80. Sheng WD et al. Treatment of chloroquine-resistant malaria using pyrimethamine in combination with berberine, tetracycline or cotrimoxazole. East Afr Med J. 1997;74:283-284.
81. Dkhil MA et al. Berberine protects against murine malaria-induced spleen tissue damage. Biomed Res. 2015;26(2):333-337.
82. Dkhil MA et al. Role of berberine in ameliorating Schistosoma mansoni-induced hepatic injury in mice. Biol Res. 2014;47:8.
83. Obrenovich ME. Leaky gut, leaky brain? Microorganisms. 2018;6(4):107.
84. Lee B et al. Tight junction in the intestinal epithelium: its association with diseases and regulation by phytochemicals. J Immunol Res. 2018;2018:2645465.
85. Li D et al. Amelioration of intestinal barrier dysfunction by berberine in the treatment of nonalcoholic fatty liver disease in rats. Pharmacogn Mag. 2017;13(52):677-682.
86. Li N et al. Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cell. Eur J Pharm Sci. 2010;40:1-8.
87. Gu L et al. Berberine ameliorates intestinal epithelial tight-junction damage and down-regulates myosin light chain kinase pathways in a mouse model of endotoxinemia. J Infect Dis. 2011;203:1602-12.
88. Cao M et al. Amelioration of IFN-γ and TNF-α-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway. PLoS One. 2013;8(5):e61944.
89. Shan CY et al. Alteration of the intestinal barrier and GLP2 secretion in berberine-treated type 2 diabetic rats. J Endocrinol. 2013;218(3):255-62.
90. Zhang Q et al. Preventive effect of Coptis chinensis and berberine on intestinal injury in rats challenged with lipopolysaccharides. Food Chem Toxicol. 2011;49(1):61-69.
91. Hou Q et al. Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBSD mice. Biomed Pharmacother. 2019;118:109206.
92. Amasheh M et al. TNFalpha-induced and berberine-antagonized tight junction barrier impairment via tyrosine kinase, Akt and NFkappaB signaling. J Cell Sci. 2010;123(Pt 23):4145-55.
93. Han J et al. Modulating gut microbiota as an anti-diabetic mechanism of berberine. Med Sci Monit. 2011;17: RA164-RA167.
94. Liu D et al. Berberine modulates gut microbiota and reduces insulin resistance via the TLR4 signaling pathway. Exp Clin Endocrinol Diabetes. 2018;126(8):513-520.
95. Yue M et al. The gut microbiota modulator berberine ameliorates collagen-induced arthritis in rats by facilitating the generation of butyrate and adjusting the intestinal hypoxia and nitrate supply. FASEB J. 2019:fj201900425RR.
96. Peng L et al. Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619-25.
97. Zhu L et al. Berberine treatment increases Akkermansia in the gut and improves high-fat diet-induced atherosclerosis in Apoe(-/-) mice. Atherosclerosis. 2018;268:117-26.
98. Zhang X. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PloS One 2012;7:e42529.
99. Shi Y et al. Berberine treatment reduces atherosclerosis by mediating gut microbiota in apoE-/- mice. Biomed Pharmacother. 2018;107:1556-1563.
100. Wang Y et al. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017;70:72-84.
101. Chen C et al. A randomized clinical trial of berberine hydrochloride in patients with diarrhea-predominant irritable bowel syndrome. Phytother Res. 2015;29(11):1822-7.
102. Kong LD et al. Monoamine oxidase inhibitors from rhizoma of Coptis chinensis. Planta Med. 2001;67:74-76.
103. Feng Y et al. Inhibiting roles of berberine in gut movement of rodents are related to activation of the endogenous opioid system. Phytother Res. 2013;27:1564-1571.
104. Chen C et al. Berberine improves intestinal motility and visceral pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome (IBS-D) symptoms in an opioid-receptor dependent manner. PLoS One. 2015;10(12):e0145556.
105. Hong T et al. Suppressive effect of berberine on experimental dextran sulfate sodium-induced colitis. Immunopharmacol Immunotoxicol. 2012;34(3):391-7.
106. Li C et al. Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation. Mol Immunol. 2015;67(2 Pt B):444-54.
107. Yasuda K et al. The pathogenicity of Th17 cells in autoimmune diseases. Semin Immunopathol. 2019;41(3):283-297.
108. Cui G et al. Berberine differentially modulates the activities of ERK, p38 MAPK, and JNK to suppress Th17 and Th1 T cell differentiation in type 1 diabetic mice. J Biol Chem. 2009;284(41):28420-9.
109. Broom OJ et al. Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin Exp Immunol. 2009;158(3):272-80.
110. Cui H et al. Berberine regulates Treg/Th17 balance to treat ulcerative colitis through modulating the gut microbiota in the colon. Front Pharmacol. 2018;9:571.
111. Zhu L et al. Protective effects of berberine hydrochloride on DSS-induced ulcerative colitis in rats. Int Immunopharmacol. 2019;68:242-251.
112. Choo BK et al. Berberine protects against esophageal mucosal damage in reflux esophagitis by suppressing proinflammatory cytokines. Exp Ther Med. 2013;6(3):663-670.
113. Li G et al. Berberine inhibits acute radiation intestinal syndrome in human with abdomen radiotherapy. Med Oncol. 2010;27:919-925.
114. Zhang Y et al. Berberine hydrochloride prevents postsurgery intestinal adhesion and inflammation in rats. J Pharmacol Exp Ther. 2014;349(3):417-26.
115. Allijn IE et al. Head-to-head comparison of anti-inflammatory performance of known natural products in vitro. PLoS ONE 2016;1(5): e0155325.
116. Allijn IE et al. Environmental impact of switching from the synthetic glucocorticoid prednisolone to the natural alkaloid berberine. PLoS One. 2018;13(6):e0199095.
117. Pérez-Rubio KG et al. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2013;11(5):366-9.
118. Yang J et al. Berberine improves insulin sensitivity by inhibiting fat store and adjusting adipokines profile in human preadipocytes and metabolic syndrome patients. Evid Based Complement Alternat Med.
2012;2012:363845.
119. Tabeshpour J et al. A review of the effects of Berberis vulgaris and its major component, berberine, in metabolic syndrome. Iran J Basic Med Sci. 2017;20(5):557-568.
120. Liang Y et al. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. Endocr J. 2019;66(1):51-63.
121. Cicero AFG et al. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci. 2017;13(5):965-1005.
122. Zhang LS et al. Efficacy and safety of berberine alone or combined with statins for the treatment of hyperlipidemia: a systematic review and meta-analysis of randomized controlled clinical trials. Am J Chin Med.
2019;47(4):751-767.
123. Zhao W et al. Reduction of blood lipid by berberine in hyperlipidemic patients with chronic hepatitis or liver cirrhosis. Biomed Pharmacother. 2008;62:730-1.
124. Kong WJ et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344-1351.
125. Doggrell SA. Berberine--a novel approach to cholesterol lowering. Expert Opin Investig Drugs. 2005;14(5):683-5.
126. Dong H et al. The effects of berberine on blood lipids: a systemic review and meta-analysis of randomized controlled trials. Planta Med. 2013;79(6):437-46.
127. Ju J et al. Efficacy and safety of berberine for dyslipidaemias: A systematic review and meta-analysis of randomized clinical trials. Phytomedicine. 2018;50:25-34.
128. Koppen LM et al. Efficacy of berberine alone and in combination for the treatment of hyperlipidemia: a systematic review. J Evid Based Complementary Altern Med. 2017;22(4):956-968.
129. Gearing ME. A potential new weapon against heart disease: PCSK9 inhibitors. Harvard University, 2015. http://sitn.hms.harvard.edu/flash/2015/a-potential-new-weapon-against-he...
130. Cameron J et al. Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 2008;201(2):266-73.
131. Dong B et al. Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1α protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem. 2015;290(7):4047-58.
132. Firouzi S et al. Barberry in the treatment of obesity and metabolic syndrome: possible mechanisms of action. Diabetes Metab Syndr Obes. 2018;11:699-705.
133. Zhang Z et al. Berberine activates thermogenesis in white and brown adipose tissue. Nat Commun. 2014;5:5493.
134. Wu L et al. Berberine promotes the recruitment and activation of brown adipose tissue in mice and humans. Cell Death Dis. 2019;10(6):468.
135. DiNicolantonio JJ et al. Astaxanthin plus berberine: a nutraceutical strategy for replicating the benefits of a metformin/fibrate regimen in metabolic syndrome. Open Heart. 2019;6:e000977.
136. Lee YS et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 2006;55:2256-64.
137. Zhou L et al. Berberine acutely inhibits insulin secretion from beta-cells through 3’,5’-cyclic adenosine 5’-monophosphate signaling pathway. Endocrinol. 2008;149:4510-4518
138. Kong WJ et al. Berberine reduces insulin resistance through protein kinase C-dependent up-regulation of insulin receptor expression. Metabolism 2009;58:109-119.
139. Xie W et al. Diabetes is an inflammatory disease: evidence from traditional Chinese medicines. Diabetes Obes Metab. 2011;13(4):289-301.
140. Yin J et al. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712-717. 141. Zhang Y et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559-65.
142. Rao A. Efficacy of berberine hydrochloride on biochemical parameters in Indian type 2 diabetic patients. Endocrine Practice 2017;23:18A.
143. Derosa G et al. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther. 2012;12:1113-24.
144. Chang W et al. Berberine as a therapy for type 2 diabetes and its complications: from mechanism of action to clinical studies. Biochem Cell Biol. 2015;93(5):479-86.
145. Chang X et al. Lipid profiling of the therapeutic effects of berberine in patients with nonalcoholic fatty liver disease. J Transl Med. 2016;14:266.
146. Pagadala M et al. Role of ceramides in nonalcoholic fatty liver disease. Trends Endocrinol Metab. 2012;23(8):365-71.
147. Zhang Z et al. Berberine prevents progression from hepatic steatosis to steatohepatitis and fibrosis by reducing endoplasmic reticulum stress. Sci Rep. 2016;6:20848.
148. Wang N et al. Berberine inhibition of fibrogenesis in a rat model of liver fibrosis and in hepatic stellate cells. Evid Based Complement Alternat Med. 2016;2016:8762345.
149. Wu JF et al. Effects of berberine on platelet aggregation and plasma levels of TXB2 and 6-keto-PGF1 alpha in rats with reversible middle cerebral artery occlusion. Yao Hsueh Hsueh Pao. 1995;30:98-102.
150. Zeng XH et al. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 2003;92(2):173-176.
151. Zheng H et al. Antimicrobial natural product berberine is efficacious for the treatment of atrial fibrillation. Biomed Res Int. 2017;2017:3146791.
152. Liu DQ et al. Berberine protects against ischemia-reperfusion injury: A review of evidence from animal models and clinical studies. Pharmacol Res. 2019;148:104385.
153. Morris G et al. Leaky brain in neurological and psychiatric disorders: drivers and consequences. Aust N Z J Psychiatry. 2018;52(10):924-948.
154. Zhu X et al. Effects of berberine on a rat model of chronic stress and depression via gastrointestinal tract pathology and gastrointestinal flora profile assays. Mol Med Rep. 2017;15(5):3161-3171.
155. Cai Z et al. Role of blood-brain barrier in Alzheimer's disease. J Alzheimers Dis. 2018;63(4):1223-1234.
156. Nation DA et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270-276.
157. Gray MT et al. Striatal blood-brain barrier permeability in Parkinson's disease. J Cereb Blood Flow Metab. 2015;35(5):747-50.
158. Kelly JR et al. Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci. 2015;9:392.
159. Rezaee R et al. Berberine alleviates paclitaxel-induced neuropathy. J Pharmacopuncture. 2019;22(2):90-94.
160. Liu YM et al. Berberine attenuates depressive-like behaviors by suppressing neuro-inflammation in stressed mice. Brain Res Bull. 2017;134:220-227.
161. Deng Z et al. Berberine protects against chronic social defeat stress-induced depressive-like behaviors with upregulation of neuronal PAS domain protein 4/brain-derived neurotrophic factor signaling pathway.
Pharmacognosy Magazine. 2018;14(58):501-506.
162. Björkholm C et al. BDNF - a key transducer of antidepressant effects. Neuropharmacology. 2016;102:72-9.
163. Tarrago T et al. The natural product berberine is a human prolyl oligopeptidase inhibitor. Chem Med Chem.
2007;2:354-359.
164. Lin X et al. Berberine: pathways to protect neurons. Phytother Res. 2018;32(8):1501-1510.
165. Jiang W et al. Therapeutic effect of berberine on Huntington's disease transgenic mouse model. PLoS One. 2015;10(7):e0134142.
166. Yuan NN et al. Neuroprotective effects of berberine in animal models of Alzheimer’s disease: a systematic review of pre-clinical studies. BMC Complement Altern Med. 2019;19(1):109.
167. Wang J et al. Neuroprotective effect of berberine agonist against impairment of learning and memory skills in severe traumatic brain injury via Sirt1/p38 MAPK expression. Mol Med Rep. 2018;17(5):6881-6886.
168. Ghotbi Ravandi S et al. Ameliorating effects of berberine on MK-801-induced cognitive and motor impairments in a neonatal rat model of schizophrenia. Neurosci Lett. 2019;706:151-157.
169. Lee B et al. Berberine alleviates symptoms of anxiety by enhancing dopamine expression in rats with posttraumatic stress disorder. Korean J Physiol Pharmacol 2018;22(2):183-192.
170. An Y et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf). 2014;80(3):425-31.
171. Li W et al. Berberine suppresses IL-33-induced inflammatory responses in mast cells by inactivating NF-κB and p38 signaling. Int Immunopharmacol. 2019;66:82-90.
172. Fu S et al. Berberine suppresses mast cell-mediated allergic responses via regulating FcɛRI-mediated and MAPK signaling. Int Immunopharmacol. 2019;71:1-6.
173. Li W et al. MicroRNA-21-mediated inhibition of mast cell degranulation involved in the protective effect of berberine on 2,4-dinitrofluorobenzene-induced allergic contact dermatitis in rats via p38 pathway. Inflammation 2018;41(2):689-699.
174. Yang N et al. Berberine and limonin suppress IgE production by human B cells and peripheral blood mononuclear cells from food-allergic patients. Ann Allergy Asthma Immunol. 2014;113(5):556-564.
175. Sakat MS et al. The ameliorative effect of berberine and coenzyme Q10 in an ovalbumin-induced allergic rhinitis model. Eur Arch Otorhinolaryngol. 2018;275(10):2495-2505.
176. Chekalina SI et al. Effect of berberine bisulfate on platelet hemostasis in thrombocytopenia patients. Gematol Transfuziol 1994;39:33-35.
177. Jiang XW et al. Effects of berberine gelatin on recurrent aphthous stomatitis: a randomized, placebocontrolled, double-blind trial in a Chinese cohort. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;115(2):212-7.
178. Imenshahidi M et al. Berberis vulgaris and berberine: an update review. Phytoth Res. 2016;30(11):1745-1764.
179. Winder WW et al. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol. 1999;277(1):E1-10.
180. Brusq JM et al. Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine. J Lipid Res 2006;47:1281-1288.
181. Chueh WH et al. Protective effect of isoquinoline alkaloid berberine on spontaneous inflammation in the spleen, liver and kidney of non-obese diabetic mice through down-regulating gene expression ratios of pro-/antiinflammatory and Th1/Th2 cytokines. Food Chem. 2012;131:1263-71.
182. Li G et al. Antifibrotic cardioprotection of berberine via downregulating myocardial IGF-1 receptorregulated MMP-2/MMP-9 expression in diabetic rats. Am J Physiol Heart Circ Physiol. 2018;315(4):H802-H813.
183. Dong S et al. Berberine could ameliorate cardiac dysfunction via interfering myocardial lipidomic profiles in the rat model of diabetic cardiomyopathy. Front Physiol. 2018;9:1042.
184. Zhu L et al. Berberine ameliorates diabetic nephropathy by inhibiting TLR4/NF-κB pathway. Biol Res. 2018:51(1);9.
185. Ni WJ et al. Berberine as a promising anti-diabetic nephropathy drug: An analysis of its effects and mechanisms. Eur J Pharmacol. 2015;760:103-12.
186. Dong J et al. Berberine ameliorates diabetic neuropathic pain in a rat model: involvement of oxidative stress, inflammation, and μ-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol. 2019;392(9):1141-1149.
187. Yerra VG et al. Adenosine monophosphate-activated protein kinase modulation by berberine attenuates mitochondrial deficits and redox imbalance in experimental diabetic neuropathy. Neuropharmacology.
2018;131:256-270.
188. Wang S et al. Berberine alleviates tau hyperphosphorylation and axonopathy-associated with diabetic encephalopathy via restoring PI3K/Akt/GSK3β pathway. J Alzheimers Dis. 2018;65(4):1385-1400.
189. Tian P et al. Leukocytes from diabetic patients kill retinal endothelial cells: effects of berberine. Mol Vis. 2013;19:2092-105.
190. Liu Y et al. Protective effects of berberine on radiation-induced lung injury via intercellular
adhesion molecular-1 and transforming growth factor-beta-1 in patients with lung cancer. Eur J Cancer. 2008;44:2425-32.
191. Liu D et al. A natural isoquinoline alkaloid with antitumor activity: studies of the biological activities of berberine. Front Pharmacol. 2019;10:9.
192. Xu J et al. Anticancer effect of berberine based on experimental animal models of various cancers: a systematic review and meta-analysis. BMC Cancer. 2019;19:589.
193. Wang N et al. Berberine and coptidis rhizoma as potential anticancer agents: recent updates and future perspectives. J Ethnopharmacol. 2015;176:35-48.
194. Crusz SM et al. Inflammation and cancer: advance and new agents. Nat Rev Clin Oncol. 2015;12:584-96.
195. Ortiz LM et al. Berberine, an epiphany against cancer. Molecules 2014;19:12349-67.
196. Guo Y et al. Repeated administration of berberine inhibits cytochromes P450 in humans. Eur J Clin Pharmacol. 2012;68(2):213-7.
197. Colombo D et al. Cyclosporine and herbal supplement interactions. J Toxicol. 2014;2014:145325.
198. Huang XS et al. Effect of berberin hydrochloride on blood concentration of cyclosporine A in cardiac transplanted recipients. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008;28(8):702-4.
199. Wu X et al. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol. 2005;61(8):567-72.
200. Feng P et al. The enhancement of cardiotoxicity that results from inhibiton of CYP 3A4 activity and hERG channel by berberine in combination with statins. Chem Biol Interact. 2018;293:115-23.
201. Galletti F et al. Efficacy of a nutraceutical combination on lipid metabolism in patients with metabolic syndrome: a multicenter, double blind, randomized, placebo controlled trial. Lipids Health Dis. 2019;18(1):66.
202. Gholampour F et al. Berberine protects the liver and kidney against functional disorders and histological damages induced by ferrous sulfate. Iran J Basic Med Sci. 2018;21:476-482.
203. Hasanein P et al. Effects of isoquinoline alkaloid berberine on lipid peroxidation, antioxidant defense system, and liver damage induced by lead acetate in rats. Redox Rep. 2017;22(1):42-50.
204. Hasanein P et al. Preventive use of berberine in inhibition of lead-induced renal injury in rats. Environ Sci Pollut Res Int. 2018;25(5):4896-4903.
205. Pan LR et al. Roles of nitric oxide in protective effect of berberine in ethanol-induced gastric ulcer mice. Acta Pharmacol Sin. 2005;26(11):1334-8.